Ovid Therapeutics Inc. (OVID), a biopharmaceutical company developing medicines for epilepsies, has multiple milestones scheduled over the next 15 months.
The company's lead drug candidate is Soticlestat, a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com